Foresight Diagnostics
Foresight Diagnostics is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
HOVON 176: Golcadomide (CC-99282) for relapsed and refractory primary large B-cell lymphoma of the central nervous system and secondary central nervous system lymphoma: a phase 2 study
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Foresight Diagnostics?
The 2026-10-09 snapshot links Foresight Diagnostics to 5 distinct CTIS trials. Recorded services include Laboratory services, ctDNA analysis, ctDNA analysis for MRD, ctDNA Testing, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Foresight Diagnostics?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Foresight Diagnostics conducted?
The linked trials record locations in 21 countries, including France, Germany, Italy, Austria, Czechia. These are trial locations, not confirmed office locations or countries where Foresight Diagnostics delivered services.
What can this page tell me about Foresight Diagnostics's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Foresight Diagnostics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Foresight Diagnostics, Inc